The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
A Single Ketamine Infusion Combined With Mindfulness-Based Behavioral Modification to Treat Cocaine Dependence: A Randomized Clinical Trial
Abstract
OBJECTIVE: Research has suggested that subanesthetic doses of ketamine may work to improve cocaine-related vulnerabilities and facilitate efforts at behavioral modification. The purpose of this trial was to test whether a single ketamine infusion improved treatment outcomes in cocaine-dependent adults engaged in mindfulness-based relapse prevention. METHODS: Fifty-five cocaine-dependent individuals were randomly assigned to receive a 40-minute intravenous infusion of ketamine (0.5 mg/kg) or midazolam (the control condition) during a 5-day inpatient stay, during which they also initiated a 5-week course of mindfulness-based relapse prevention. Cocaine use was assessed through self-report and urine toxicology. The primary outcomes were end-of-study abstinence and time to relapse (defined as first use or dropout). RESULTS: Overall, 48.2% of individuals in the ketamine group maintained abstinence over the last 2 weeks of the trial, compared with 10.7% in the midazolam group (intent-to-treat analysis). The ketamine group was 53% less likely (hazard ratio=0.47; 95% CI=0.24, 0.92) to relapse (dropout or use cocaine) compared with the midazolam group, and craving scores were 58.1% lower in the ketamine group throughout the trial (95% CI=18.6, 78.6); both differences were statistically significant. Infusions were well tolerated, and no participants were removed from the study as a result of adverse events. CONCLUSIONS: A single ketamine infusion improved a range of important treatment outcomes in cocaine-dependent adults engaged in mindfulness-based behavioral modification, including promoting abstinence, diminishing craving, and reducing risk of relapse. Further research is needed to replicate these promising results in a larger sample.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Significant reductions in cocaine use were also observed after ketamine administration in a randomized, controlled trial (n = 55) of ketamine in combination with mindfulness-based behavioral interventions [149]”
From Ketamine in neuropsychiatric disorders: an update (2024) · cites this paper as [149]
In the citing paper
“This was effectively demonstrated in three recent studies, which, utilising a combined design, produced beneficial trait-alterations, as well as enhancements in mood, satisfaction with life and behavioural change, which were more significant and longer-lasting than previously observed changes, when each intervention was used in isolation (60–62).”
From Examining the Potential Synergistic Effects Between Mindfulness Training and Psychedelic-Assisted Therapy (2021) · cites this paper as [62]
In the citing paper
“Participants in the ketamine group demonstrated higher post-acute and long-term abstinence rates, in comparison to the control group. 48.2% abstinence was observed for participants in the ketamine group at the end of the study, compared to 10.7% for the control group, and such high rates of abstinence were maintained at 6 months for the experimental group, whilst all participants in the control”
From Examining the Potential Synergistic Effects Between Mindfulness Training and Psychedelic-Assisted Therapy (2021) · cites this paper as [62]
Citations
Cites
Development, reliability, and validity of a dissociation scale
BERNSTEIN, E. M., & PUTNAM, F. W. (1986) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-198612000-00004 · Cited by 3,793 · cited 9×
“The Clinician-Administered Dissociative States Scale (CADSS) (30) was administered at the conclusion of the infusion by a trained research assistant.”
MethodInfluentialGoldstein, R. Z., & Volkow, N. D. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.10.1642 · Cited by 2,667 · cited 1×
“A line of pharmacotherapy research that holds promise is modulation of glutamate neurotransmission (2, 3).”
BackgroundWilamowska (2010) · doi:10.1001/archpsyc.1988.01800320058007 · Cited by 2,115 · cited 4×
“Baseline clinical and demographic characteristics of participants in a randomized controlled trial of ketamine and a mindfulness-based behavioral modification for cocaine dependencea Characteristic Total Sample (N=55) Midazolam Group (N=28) Ketamine Group (N=27) Mean SD Mean SD Mean SD Age (years) 47.0 9.3 48.9 11.0 4…”
MethodInfluentialMindfulness practice leads to increases in regional brain gray matter density
Hölzel, B. K., Carmody, J., Vangel, M., Congleton, C., Yerramsetti, S. M., Gard, T., & Lazar, S. W. (2011) · Psychiatry Research: Neuroimaging · doi:10.1016/j.pscychresns.2010.08.006 · Cited by 1,914
The brain on drugs: from reward to addiction
Volkow, N. D., & Morales, M. (2015) · Cell · doi:10.1016/j.cell.2015.07.046 · Cited by 1,306 · cited 2×
“A line of pharmacotherapy research that holds promise is modulation of glutamate neurotransmission (2, 3).”
BackgroundNeural correlates of attentional expertise in long-term meditation practitioners
Brefczynski-Lewis, J. A., Lutz, A., Schaefer, H. S., Levinson, D. B., & Davidson, R. J. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0606552104 · Cited by 983
Bremner, J. D., Krystal, J. H., Putnam, F. W., Southwick, S. M., Marmar, C., Charney, D. S., & Mazure, C. M. (1998) · Journal of Traumatic Stress · doi:10.1023/a:1024465317902 · Cited by 817 · cited 3×
“The Clinician-Administered Dissociative States Scale (CADSS) (30) was administered at the conclusion of the infusion by a trained research assistant.”
MethodInfluentialMindfulness-Based Relapse Prevention for Substance Use Disorders: A Pilot Efficacy Trial
Bowen, S., Chawla, N., Collins, S. E., Witkiewitz, K., Hsu, S., Grow, J., Clifasefi, S., Garner, M., Douglass, A., Larimer, M. E., et al. (2009) · Substance Abuse · doi:10.1080/08897070903250084 · Cited by 715 · cited 1×
“Mindfulness-based relapse prevention (MBRP), a manualized treatment that has demonstrated modest efficacy for substance use disorders (13, 14),may be especiallywell suited as a behavioral counterpart to ketamine.”
BackgroundReliability of the Timeline Followback for cocaine, cannabis, and cigarette use
Robinson, S. M., Sobell, L. C., Sobell, M. B., & Leo, G. I. (2014) · Psychology of Addictive Behaviors · doi:10.1037/a0030992 · Cited by 699 · cited 1×
“Measures related to cocaine-related vulnerabilities, such as craving (assessed using a visual analogue scale), mindfulness (the Five-Facet Mindfulness Questionnaire), and stress sensitivity (the Perceived Stress Scale), were collected at each visit, aswell as urine toxicology (12-panel dipstick, including ketamine) an…”
MethodSide-effects associated with ketamine use in depression: a systematic review
Short, B., Fong, J., Galvez, V., Shelker, W., & Loo, C. K. (2018) · The Lancet Psychiatry · doi:10.1016/s2215-0366(17)30272-9 · Cited by 558
Research works printed but not linked: 3
- Sheehan DV, 1998, J Clin Psychiatry, 59, 22
- First MB, 2007, Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Clinical Trials Version (SCID-CT)
- Stahl S, 2008, Essential Psychopharmacology: Neuroscientific Basis and Clinical Applications
Cited by
McIntyre, R. S., Berk, M., Brietzke, E., Goldstein, B. I., López-Jaramillo, C., Kessing, L. V., Malhi, G. S., Nierenberg, A. A., Rosenblat, J. D., Majeed, A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31544-0 · Cited by 1,047
McIntyre, R. S., Rosenblat, J. D., Nemeroff, C. B., Sanacora, G., Murrough, J. W., Berk, M., Brietzke, E., Dodd, S., Gorwood, P., Ho, R., et al. (2021) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2020.20081251 · Cited by 731
“Preliminary evidence suggests that single-dose intravenous racemic ketamine, in combination with manual-based psychosocial treatment, may attenuate alcohol and cocaine craving and consumption (130, 131).”
BackgroundPsychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms
Inserra, A., De Gregorio, D., & Gobbi, G. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000056 · Cited by 232
Breeksema, J. J., Niemeijer, A. R., Krediet, E., Vermetten, E., & Schoevers, R. A. (2020) · CNS Drugs · doi:10.1007/s40263-020-00748-y · Cited by 224
Improving translation of animal models of addiction and relapse by reverse translation
Venniro, M., Banks, M. L., Heilig, M., Epstein, D. H., & Shaham, Y. (2020) · Nature Reviews Neuroscience · doi:10.1038/s41583-020-0378-z · Cited by 212
Metadata
- Authors
- Dakwar, E., Nunes, E. V., Hart, C. L., Foltin, R. W., Mathew, S. J., Carpenter, K. M., Choi, C. J. “., Basaraba, C. N., Pavlicova, M., & Levin, F. R.
- Affiliations
- Baylor College of Medicine (US)
- New York State Psychiatric Institute, Columbia University Medical Center, New York (Dakwar, Nunes, Hart, Foltin, Carpenter, Levin); the Department of Psychology, Columbia University, New York (Hart); the Department of Psychiatry, Baylor College of Medicine, Houston (Mathew); New York State Psychiatric Institute, Division of Biostatistics, New York (Choi, Basaraba); and the Department of Biostatistics, Columbia University Medical Center, New York (Pavlicova).
- ORCID
- Venue
- American Journal of Psychiatry
- Published
- 2019-11-01
- Volume
- 176
- Issue
- 11
- Pages
- 923-930
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W2953529230
- Cited by
- 186
- References
- 37
- Citations by year
- 2026: 22 · 2025: 39 · 2024: 29 · 2023: 21 · 2022: 33 · 2021: 19 · 2020: 18 · 2019: 5
- FWCI
- 14.29
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Journal of Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Keywords
- ketamine, cocaine dependence, mindfulness-based relapse prevention, cocaine craving, cocaine abstinence, relapse prevention, addiction treatment
- MeSH terms
- Combined Modality Therapy, Female, Humans, Infusions, Intravenous, Ketamine, Male, Midazolam, Middle Aged, Treatment Outcome, Excitatory Amino Acid Antagonists, Cocaine-Related Disorders, Mindfulness
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Single Ketamine Infusion Combined With Mindfulness-Based Behavioral Modification to Treat Cocaine Dependence: A Randomized Clinical Trial. https://app.cochat.ai/papers/10.1176/appi.ajp.2019.18101123
- The paper
- Dakwar, E., Nunes, E. V., Hart, C. L., Foltin, R. W., Mathew, S. J., Carpenter, K. M., Choi, C. J. “., Basaraba, C. N., Pavlicova, M., & Levin, F. R. (2019). A Single Ketamine Infusion Combined With Mindfulness-Based Behavioral Modification to Treat Cocaine Dependence: A Randomized Clinical Trial. American Journal of Psychiatry. https://doi.org/10.1176/appi.ajp.2019.18101123
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.